Lauren Leiman,
Executive Director,
Blood Profiling Atlas in Cancer (BloodPAC)
Lauren C. Leiman is the Executive Director of the Blood Profiling Atlas in Cancer (BloodPAC), a consortium focused on creating an open database for liquid biopsies to accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit. Prior to running BloodPAC, she was the Senior Director of External Partnerships at White House Cancer Moonshot Task Force during the Obama Administration. Previously, Lauren was a Senior Advisor for the Melanoma Research Alliance and Director of Philanthropy at Elysium Management LLC in New York City. From 2008-2010, Lauren worked for the Millennium Promise Alliance, where she led the major gifts fundraising effort and spent significant time in sub-Saharan Africa. Lauren was also the head of marketing and investor relations at Steel Partners, LP, an activist hedge fund investing globally. Lauren received her undergraduate degree in communications from the University of Pennsylvania's Annenberg School. She also holds an MBA in international business from the University of North Carolina's Kenan-Flagler Business School and a master's degree in public relations and corporate communications from New York University (NYU).
BloodPAC: Establishing Standards and Aggregating Data to Accelerate Development, Approval and Accessibility of Liquid Biopsy Technology
Wednesday, 2 March 2022 at 16:30
Add to Calendar ▼2022-03-02 16:30:002022-03-02 17:30:00Europe/LondonBloodPAC: Establishing Standards and Aggregating Data to Accelerate Development, Approval and Accessibility of Liquid Biopsy TechnologyCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
The Blood Profiling Atlas in Cancer (BloodPAC) looks to improve outcomes for patients with cancer. To address this challenge, BloodPAC established a collaborative infrastructure to develop standards and best practices, organize and coordinate research studies through its members and operate the BloodPAC Data Commons (BPDC) to support the exchange of raw and processed data generated by the liquid biopsy research community. Data from retrospective basic, clinical and regulatory member studies, as well as projects BloodPAC has prospectively organized since its inception, is aggregated and contributed to the BPDC to establish an open, publicly accessible data commons for the global liquid biopsy community. Today, the BloodPAC is entirely member funded and member driven. In addition to developing standards and aggregating data, BloodPAC works collaboratively with all stakeholders in the field to broaden awareness and implementation of the suggested guidelines and establish a wider chain of feedback and discussion in the community. BloodPAC’s unique approach to collaboration in the field has led to the organization’s success and helps to guide our work into the future.
Add to Calendar ▼2022-03-01 00:00:002022-03-02 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-03-02 16:30:002022-03-02 17:30:00Europe/LondonBloodPAC: Establishing Standards and Aggregating Data to Accelerate Development, Approval and Accessibility of Liquid Biopsy TechnologyCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
